A clinical evaluation of a prolonged schedule of cytosine arabinoside (NSC63878).
D000230:Adenocarcinoma / Q000188:drug therapy; D001773:Blood Cells / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy; D002277:Carcinoma / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy; D007958:Leukocyte Count; D008099:Liver / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy; D014516:Ureteral Neoplasms / Q000188:drug therapy; D014523:Urethral Neoplasms / Q000188:drug therapy
D003561:Cytarabine